Fate of the Trump Administration's Controversial Most Favored Nation Drug Pricing Unclear
Advertisement The Fate of the Trump Administration’s Controversial Most Favored Nation Drug Pricing Model Is Unclear Given Mounting Legal Challenges Thursday, December 10, 2020 On November 27, 2020, CMS published its Most Favored Nation (MFN) Model Interim Final Rule (IFR) that seeks to lower the amount paid for 50 high-cost Medicare Part B drugs to the lowest price that drug manufacturers receive in similar countries.[1] CMS utilized its purported authority under the Affordable Care Act (ACA) to implement a pricing model via its Center for Medicare and Medicaid Innovation (CMMI)...
Source: natlawreview.com